The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Targeted disruption of the EZH2–EED complex inhibits EZH2-dependent cancer
Open accessAbstract
Enhancer of zeste homolog2 (EZH2) is the histone lysine N-methyltransferase component of the Polycomb repressive complex 2 (PRC2), which in conjunction with embryonic ectoderm development (EED) and suppressor of zeste 12 homolog (SUZ12), regulates cell lineage determination and homeostasis. Enzymatic hyperactivity has been linked to aberrant repression of tumor suppressor genes in diverse cancers. Here, we report the development of stabilized alpha-helix of EZH2 (SAH-EZH2) peptides that selectively inhibit H3 Lys27 trimethylation by dose-responsively disrupting the EZH2/EED complex and reducing EZH2 protein levels, a mechanism distinct from that reported for small molecule EZH2 inhibitors targeting the enzyme catalytic domain. MLL-AF9 leukemia cells, which are dependent on PRC2, undergo growth arrest and monocyte/macrophage differentiation upon treatment with SAH-EZH2, consistent with observed changes in expression of PRC2-regulated, lineage-specific marker genes. Thus, by dissociating the EZH2/EED complex, we pharmacologically modulate an epigenetic “writer” and suppress PRC2-dependent cancer cell growth.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of human brain tumour initiating cells
Singh, S. K., Hawkins, C., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., Henkelman, R. M., Cusimano, M. D., & Dirks, P. B. (2004) · Nature · doi:10.1038/nature03128 · Cited by 7,433
Chou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163
Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., et al. (2012) · Nature · doi:10.1038/nature11606 · Cited by 1,786
Kleer, C. G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S. A., Ghosh, D., Sewalt, R. G. A. B., Otte, A. P., Hayes, D. F., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1933744100 · Cited by 1,649
Kuzmichev, A., Nishioka, K., Erdjument-Bromage, H., Tempst, P., & Reinberg, D. (2002) · Genes & Development · doi:10.1101/gad.1035902 · Cited by 1,596 · cited 3×
“The conserved suppressor of variegation, enhancer of zeste, trithorax (SET) domain of EZH2 contains the active site for catalysis of H3K27 methylation 4 .”
Histone Methyltransferase Activity of a Drosophila Polycomb Group Repressor Complex
Müller, J., Hart, C. M., Francis, N. J., Vargas, M. L., Sengupta, A., Wild, B., Miller, E. L., O'Connor, M. B., Kingston, R. E., & Simon, J. A. (2002) · Cell · doi:10.1016/s0092-8674(02)00976-5 · Cited by 1,562
Czermin, B., Melfi, R., McCabe, D., Seitz, V., Imhof, A., & Pirrotta, V. (2002) · Cell · doi:10.1016/s0092-8674(02)00975-3 · Cited by 1,533
Morin, R. D., Johnson, N. A., Severson, T. M., Mungall, A. J., An, J., Goya, R., Paul, J. E., Boyle, M., Woolcock, B. W., Kuchenbauer, F., et al. (2010) · Nature Genetics · doi:10.1038/ng.518 · Cited by 1,521
Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9
Krivtsov, A. V., Twomey, D., Feng, Z., Stubbs, M. C., Wang, Y., Faber, J., Levine, J. E., Wang, J., Hahn, W. C., Gilliland, D. G., et al. (2006) · Nature · doi:10.1038/nature04980 · Cited by 1,513 · cited 2×
“As MLL-AF9 cells are EZH2-dependent and manifest differentiation blockade due to epigenetic deregulation 34 , we monitored the impact of SAH-EZH2-mediated disruption of PRC2 activity on the morphology of treated cells.”
Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix
Walensky, L. D., Kung, A. L., Escher, I., Malia, T. J., Barbuto, S., Wright, R. D., Wagner, G., Verdine, G. L., & Korsmeyer, S. J. (2004) · Science · doi:10.1126/science.1099191 · Cited by 1,349
Self-citationCancer Genetics and Epigenetics: Two Sides of the Same Coin?
You, J. S., & Jones, P. A. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.008 · Cited by 1,167
Chromatin remodelling during development
Ho, L., & Crabtree, G. R. (2010) · Nature · doi:10.1038/nature08911 · Cited by 1,114 · cited 1×
“…“writers” bind differentially to multiple cofactors and form diverse functional complexes to maintain cellular homeostasis and regulate cell fate 49,50 , selective targeting of a pathologic methyltransferase complex may exhibit a therapeutic window and not lead to complete ‘shut off’ of an…”
Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer
Varambally, S., Cao, Q., Mani, R.-S., Shankar, S., Wang, X., Ateeq, B., Laxman, B., Cao, X., Jing, X., Ramnarayanan, K., et al. (2008) · Science · doi:10.1126/science.1165395 · Cited by 1,052
Shen, X., Liu, Y., Hsu, Y.-J., Fujiwara, Y., Kim, J., Mao, X., Yuan, G.-C., & Orkin, S. H. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.10.016 · Cited by 1,021
Self-citationTan, J., Yang, X., Zhuang, L., Jiang, X., Chen, W., Lee, P. L., Karuturi, R. K. M., Tan, P. B. O., Liu, E. T., & Yu, Q. (2007) · Genes & Development · doi:10.1101/gad.1524107 · Cited by 895 · cited 1×
“As such, EZH2 has emerged as a high priority target for therapeutic development 5–7 DZNep has been characterized as a small molecule EZH2 inhibitor that disrupts PRC2 and manifests anti-tumor activity in a variety of cancers 44–46 .”
Ezh1 and Ezh2 Maintain Repressive Chromatin through Different Mechanisms
Margueron, R., Li, G., Sarma, K., Blais, A., Zavadil, J., Woodcock, C. L., Dynlacht, B. D., & Reinberg, D. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.11.004 · Cited by 884
EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent
Xu, K., Wu, Z. J., Groner, A. C., He, H. H., Cai, C., Lis, R. T., Wu, X., Stack, E. C., Loda, M., Liu, T., et al. (2012) · Science · doi:10.1126/science.1227604 · Cited by 875
Bracken, A. P., Kleine-Kohlbrecher, D., Dietrich, N., Pasini, D., Gargiulo, G., Beekman, C., Theilgaard-Mönch, K., Minucci, S., Porse, B. T., Marine, J.-C., et al. (2007) · Genes & Development · doi:10.1101/gad.415507 · Cited by 850
Béguelin, W., Popovic, R., Teater, M., Jiang, Y., Bunting, K. L., Rosen, M., Shen, H., Yang, S. N., Wang, L., Ezponda, T., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.011 · Cited by 846
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
Knutson, S. K., Wigle, T. J., Warholic, N. M., Sneeringer, C. J., Allain, C. J., Klaus, C. R., Sacks, J. D., Raimondi, A., Majer, C. R., Song, J., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1084 · Cited by 776
Direct inhibition of the NOTCH transcription factor complex
Moellering, R. E., Cornejo, M., Davis, T. N., Bianco, C. D., Aster, J. C., Blacklow, S. C., Kung, A. L., Gilliland, D. G., Verdine, G. L., & Bradner, J. E. (2009) · Nature · doi:10.1038/nature08543 · Cited by 752
Epigenetic Antagonism between Polycomb and SWI/SNF Complexes during Oncogenic Transformation
Wilson, B. G., Wang, X., Shen, X., McKenna, E. S., Lemieux, M. E., Cho, Y.-J., Koellhoffer, E. C., Pomeroy, S. L., Orkin, S. H., & Roberts, C. W. M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.09.006 · Cited by 654
Self-citationCharacterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells
Suetsugu, A., Nagaki, M., Aoki, H., Motohashi, T., Kunisada, T., & Moriwaki, H. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.10.128 · Cited by 609
Miranda, T. B., Cortez, C. C., Yoo, C. B., Liang, G., Abe, M., Kelly, T. K., Marquez, V. E., & Jones, P. A. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0013 · Cited by 596
McCabe, M. T., Graves, A. P., Ganji, G., Diaz, E., Halsey, W. S., Jiang, Y., Smitheman, K. N., Ott, H. M., Pappalardi, M. B., Allen, K. E., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116418109 · Cited by 483
Cell-penetrating peptides: tools for intracellular delivery of therapeutics
Deshayes, S., Morris, M. C., Divita, G., & Heitz, F. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5109-0 · Cited by 483
Riss, T., Moravec, R. A., Niles, A. L., Duellman, S. J., Benink, H. A., Worzella, T. J., & Minor, L. K. (2016) · Europe PMC (PubMed Central) · Cited by 469
Jumonji Modulates Polycomb Activity and Self-Renewal versus Differentiation of Stem Cells
Shen, X., Kim, W., Fujiwara, Y., Simon, M. D., Liu, Y., Mysliwiec, M. R., Yuan, G.-C., Lee, Y., & Orkin, S. H. (2009) · Cell · doi:10.1016/j.cell.2009.12.003 · Cited by 424
Self-citationThe MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer
Stewart, M. L., Fire, E., Keating, A. E., & Walensky, L. D. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.391 · Cited by 418
Self-citationContext-Specific Regulation of NF-κB Target Gene Expression by EZH2 in Breast Cancers
Lee, S. T., Li, Z., Wu, Z., Aau, M., Guan, P., Karuturi, R. K. M., Liou, Y. C., & Yu, Q. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.08.011 · Cited by 399
A Stapled BID BH3 Helix Directly Binds and Activates BAX
Walensky, L. D., Pitter, K., Morash, J., Oh, K. J., Barbuto, S., Fisher, J., Smith, E., Verdine, G. L., & Korsmeyer, S. J. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.08.020 · Cited by 383
Self-citationEzhkova, E., Lien, W.-H., Stokes, N., Pasolli, H. A., Silva, J. M., & Fuchs, E. (2011) · Genes & Development · doi:10.1101/gad.2019811 · Cited by 357
Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic
Bird, G. H., Madani, N., Perry, A. F., Princiotto, A. M., Supko, J. G., He, X., Gavathiotis, E., Sodroski, J. G., & Walensky, L. D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002713107 · Cited by 347
Self-citationPolycomb Repressive Complex 2 Is Dispensable for Maintenance of Embryonic Stem Cell Pluripotency
Chamberlain, S. J., Yee, D., & Magnuson, T. (2008) · Stem Cells · doi:10.1634/stemcells.2008-0102 · Cited by 340
Mi-2/NuRD: multiple complexes for many purposes
Bowen, N. J., Fujita, N., Kajita, M., & Wade, P. A. (2004) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/j.bbaexp.2003.10.010 · Cited by 311
Byvoet, P., Shepherd, G. R., Hardin, J. M., & Noland, B. J. (1972) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(72)90174-9 · Cited by 238
Polycomb repressive complex 2 is required for MLL-AF9 leukemia
Neff, T., Sinha, A. U., Kluk, M. J., Zhu, N., Khattab, M. H., Stein, L., Xie, H., Orkin, S. H., & Armstrong, S. A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202258109 · Cited by 224
Self-citationYu, J., Cao, Q., Mehra, R., Laxman, B., Yu, J., Tomlins, S. A., Creighton, C. J., Dhanasekaran, S. M., Shen, R., Chen, G., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.10.016 · Cited by 223
Kong, D., Heath, E., Chen, W., Cher, M. L., Powell, I., Heilbrun, L., Li, Y., Ali, S., Sethi, S., Hassan, O., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033729 · Cited by 219
Biological Effects of Inhibitors of S-Adenosylhomocysteine Hydrolase
Chiang, P. K. (1998) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)00089-2 · Cited by 211
Enhancer of Zeste Homologue 2 (EZH2) Down-regulates RUNX3 by Increasing Histone H3 Methylation
Fujii, S., Ito, K., Ito, Y., & Ochiai, A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800224200 · Cited by 193
Borchardt, R. T., Keller, B. T., & Patel-Thombre, U. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)43053-5 · Cited by 186
EZH2 Mediates Epigenetic Silencing of Neuroblastoma Suppressor Genes CASZ1 , CLU , RUNX3 , and NGFR
Wang, C., Liu, Z., Woo, C.-W., Li, Z., Wang, L., Wei, J. S., Marquez, V. E., Bates, S. E., Jin, Q., Khan, J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-0961 · Cited by 175
Structural Basis of EZH2 Recognition by EED
Han, Z., Xing, X., Hu, M., Zhang, Y., Liu, P., & Chai, J. (2007) · Structure · doi:10.1016/j.str.2007.08.007 · Cited by 162
Shi, J., Wang, E., Zuber, J. A., Rappaport, A., Taylor, M. J., Johns, C., Lowe, S. W., & Vakoc, C. R. (2012) · Oncogene · doi:10.1038/onc.2012.110 · Cited by 125
Tullio, A. D., Manh, T. V., Schubert, A., Castellano, G., Månsson, R., & Graf, T. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112169108 · Cited by 119
EZH2 Depletion Blocks the Proliferation of Colon Cancer Cells
Fussbroich, B., Wagener, N., Macher‐Goeppinger, S., Benner, A., Fälth, M., Sültmann, H., Holzer, A., Hoppe‐Seyler, K., & Hoppe‐Seyler, F. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021651 · Cited by 114
Sasaki, M., Yamaguchi, J., Itatsu, K., Ikeda, H., & Nakanuma, Y. (2008) · The Journal of Pathology · doi:10.1002/path.2345 · Cited by 108
Toren, A., Bielorai, B., Jacob‐Hirsch, J., Fisher, T., Kreiser, D., Moran, O., Zeligson, S., Givol, D., Yitzhaky, A., Itskovitz‐Eldor, J., et al. (2005) · Stem Cells · doi:10.1634/stemcells.2004-0317 · Cited by 94
He, L., Liu, M., Li, B., Jia, W., Zhang, Y., Liao, Y.-J., Chen, Y., Zhang, L., Guan, X., Zeng, Y., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.25031 · Cited by 87
Pinto do Ó, P., Richter, K., & Carlsson, L. (2002) · Blood · doi:10.1182/blood.v99.11.3939 · Cited by 62
Momparler, R. L., Idaghdour, Y., Márquez, V. E., & Momparler, L. F. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.03.001 · Cited by 54
Hinz, S., Kempkensteffen, C., Christoph, F., Hoffmann, M. J., Krause, H., Schrader, M. G., Schostak, M., Miller, K., & Weikert, S. (2007) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-007-0288-8 · Cited by 34
Cited by
Kim, K. H., & Roberts, C. W. M. (2016) · Nature Medicine · doi:10.1038/nm.4036 · Cited by 1,471
EZH2: a novel target for cancer treatment
Duan, R., Du, W., & Guo, W. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00937-8 · Cited by 926
Hydrocarbon-Stapled Peptides: Principles, Practice, and Progress: Miniperspective
Walensky, L. D., & Bird, G. H. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4011675 · Cited by 795
Self-citationDiscovery of cancer drug targets by CRISPR-Cas9 screening of protein domains
Shi, J., Wang, E., Milazzo, J. P., Wang, Z., Kinney, J. B., & Vakoc, C. R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3235 · Cited by 761
Pelay‐Gimeno, M., Glas, A., Koch, O., & Grossmann, T. N. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201412070 · Cited by 717
Metadata
- Authors
- Kim, W., Bird, G. H., Neff, T., Guo, G., Kerenyi, M. A., Walensky, L. D., & Orkin, S. H.
- Venue
- Nature Chemical Biology
- Published
- 2013-08-25
- Volume
- 9
- Issue
- 10
- Pages
- 643-650
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- OpenAlex
- W2109613178
- Cited by
- 338
- References
- 55
- FWCI
- 16.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.